GCI Health has announced the appointment of Annalise Coady as president, UK market lead and EMEA head of growth. Coady brings over two decades of experience in building and scaling marketing communications teams to the role.
She was previously group president at Real Chemistry, where she was responsible for growing the agency’s footprint across Europe. She has held senior growth roles at Fleishman Hillard, MHP Group and, most recently, at the patient experience start-up PxC.
In her new role, Coady will lead GCI Health’s UK business and partner with Kath Harrison, president, EMEA, and the agency’s leadership team to drive new opportunities, broadening the agency’s client base in the UK, Germany and the Middle East, as well as its public affairs hub in Brussels. She will also oversee all UK operations with a dual client service and culture remit.
“The seismic changes in the delivery of healthcare globally present great opportunities for communicators,” said Coady. “I’m excited to join the… team at GCI Health who are… laser-focused on creating innovative experiences that transform the way we help our clients engage with their stakeholders.”
Dan Bunce has also been appointed as EMEA head of business development. He joins GCI Health from Syneos Health Communications and brings extensive experience in establishing frameworks for unified and sustained growth.
Bunce will be responsible for codifying the EMEA team’s approach and expanding the agency’s capabilities across the region.
“With the rapidly changing and highly complex health landscape in EMEA, our footprint and expertise across the region will help GCI Health maximise client impact around the world,” said Kristin Cahill, global chief executive officer of GCI Group. “Annalise’s and Dan’s experience make them the perfect people to lead our… team into the future…”